A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients with Variegate Porphyria (VP)-related skin disease.

Published: 21-02-2022
Last updated: 17-01-2025

Main objective: determine whether afamelanotide implants can reduce the severity of the skin disease in patients with VPSecondary objectives: Evaluate the safety and tolerability of afamelanotide in patients with VP. Evaluate the impact of...

Ethical review	Approved WMO
Status	Completed
Health condition type	Other condition
Study type	Interventional

Summary

ID

NL-OMON54663

Source
ToetsingOnline

Brief title
Phase IIa VP Study / CUV040

Condition

- Other condition
- Metabolic and nutritional disorders congenital

Synonym
porphyria variegata, variegate porphyria

Health condition

inborn error of heme biosynthesis

Research involving
Human

Sponsors and support

Primary sponsor: Clinuvel (UK) LTD
Source(s) of monetary or material Support: Study sponsor;CLINUVEL (UK) LIMITED

Intervention

Keyword: afamelanotide, photoxicity, skin disease, variegate porphyria

Outcome measures

Primary outcome

The change in severity of skin disease from baseline to Days 28, 56, 84, 112, 140 and 168 and then from Day 168 to Day 196, as measured by the 11-point VAS IGA scale.

Secondary outcome

The change in severity from baseline to Days 28, 56, 84, 112, 140 and 168 and then from Day 168 to Day 196, as measured by: The 5-point IGA; The Patient*s Global Assessment using a VAS. - The change in the number of new skin lesions formed during the preceding 28 days from baseline to Days 28, 56, 84, 112, 140 and 168 then from Day 168 to Day 196 as counted by the Investigator. - The change in Quality of Life from baseline to Day 28, 56, 84, 112, 140 and 168 then from Day 168 to Day 196, as measured by the three instruments: WPAI:GH, VP-derived QOLEB, VP-QoL. - Change in outdoors light exposure over time (Daily Diary). Trauma events will be tabulated.

Study description

Background summary

Afamelanotide 16mg has been shown to be effective in the prevention of phototoxicity in EPP and had obtained marketing authorisation in the European Union for this indication in adult patients. The results of the clinical trials conducted by CLINUVEL, as well as of one long term observational study and the ongoing post-authorisation pharmacovigilance activities, confirmed the positive safety profile of afamelanotide to date. As the photosensitising agent is the same in VP as it is in EPP, it is believed that afamelanotide could be of benefit to VP patients with cutaneous symptoms. In view of the chronic nature of the disease, and the pharmacokinetic profile of afamelanotide 16mg, an intensified dosage scheme to that used in EPP (once every 28 days rather than once every 60 days), but similar to that applied previously in vitiligo studies would be expected to be effective.

Study objective

Main objective: determine whether afamelanotide implants can reduce the severity of the skin disease in patients with VP

Secondary objectives: Evaluate the safety and tolerability of afamelanotide in patients with VP. Evaluate the impact of afamelanotide on the quality of life of patients with VP.

Study design

Afamelanotide 16 mg every 28±2 days (up to six doses), as a controlled-release implant.
This is an 8-month (including the screening and follow-up period) open label study in adult patients with confirmed VP-related skin disease.

Intervention

Afamelanotide 16 mg every 28±2 days (up to six doses)

Study burden and risks

The results of the clinical trials conducted by CLINUVEL in other indications, as well as of one long term observational study and the ongoing post-authorisation pharmacovigilance activities in erythropoietic protoporphyria (EPP) patients, confirmed the positive safety profile of afamelanotide to date. To date, SCENESSE® has been administered to more than 903 patients - EPP and other indications - and healthy volunteers in total as part of its clinical development. The most commonly reported adverse reactions are nausea, experienced by approximately 19% of subjects who received treatment with the drug during clinical studies, headache (20%), and implant site

reactions (21%; mainly discolouration, pain, haematoma, erythema). In most cases these adverse reactions are reported to be mild in severity and transient in nature. Most adverse events occur within 24-72 hours following the administration of the implant. *Participation in the study may also require time for additional hospital appointments and for matters that are necessary to meet the research requirements. Each visit lasts on average about 3 hours.*

Contacts

Public
Clinuvel (UK) LTD

Wesley House, Bull Hill 1
Leatherhead, Surrey KT22 7AH
GB
Scientific
Clinuvel (UK) LTD

Wesley House, Bull Hill 1
Leatherhead, Surrey KT22 7AH
GB

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)

Inclusion criteria

Male or female patients with confirmed diagnosis of VP.
Patients with VP-related skin symptoms assessed with a score equal or above 7 on the 11-point VAS IGA.

Exclusion criteria

Known allergy to afamelanotide or the polymer or to lignocaine/lidocaine or other local anaesthetic.
Had two or more acute attacks of hepatic porphyria lasting more than two days, within 12 months prior to the Screening period.
History of certain malignant and premalignant skin lesions.
Individual or family history of melanoma.
Severe hepatic disease.
Renal impairment (eGFR (MDRD) < 30 ml/min*1.73m2).
Female who is pregnant or lactating.
Females of child-bearing potential not using adequate contraceptive measures.
Sexually active man with a partner of child-bearing potential who is not using adequate contraceptive measures.
Not suitable for trial participation in the opinion of the Investigator.

Study design

Design

Study phase:	2
Study type:	Interventional
Masking:	Open (masking not used)
Control:	Uncontrolled
Primary purpose:	Treatment

Recruitment

NL

Recruitment status:	Completed
Start date (anticipated):	28-03-2023
Enrollment:	5
Type:	Actual

Medical products/devices used

Product type:	Medicine
Brand name:	Scenesse
Generic name:	afamelanotide

Registration:	Yes - NL outside intended use

Ethics review

Approved WMO Date:	21-02-2022
Application type:	First submission
Review commission:	METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)
Approved WMO Date:	19-05-2022
Application type:	First submission
Review commission:	METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)
Approved WMO Date:	20-02-2023
Application type:	Amendment
Review commission:	METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)
Approved WMO Date:	06-03-2023
Application type:	Amendment
Review commission:	METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)
Approved WMO Date:	16-10-2023
Application type:	Amendment
Review commission:	METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
EudraCT	EUCTR2018004164-60-NL
CCMO	NL69926.078.19